American Society of Hirudotherapy

Leech Saliva Pulmonary-Fibrosis Pharmacology (Composite)

Leech extract + saliva pharmacology relevant to pulmonary fibrosis and other fibrotic diseases (composite topic entry; no single primary publication attributed).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Leech-derived crude extract
Safety domains
Bleeding

Clinical translation limit

Preclinical pulmonary / liver fibrosis pharmacology does NOT translate to clinical efficacy. Not an FDA-cleared indication.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo medicinalis / orientalis

Biological Targets

  • → TGFβ1 pathway; collagen deposition; fibroblast activation

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.